NuProbe leverages its portfolio of ultrasensitive molecular technologies and expertise in assay development to partner with diagnostic companies to co-develop new products with improved performances.


NuProbe collaborates with diagnostic companies to provide novel solutions to enhance existing platforms and expand test menus. We have developed proprietary technologies to increase sensitivity and overall sequencing efficiency while fitting into existing workflows.

We work with our industry partners to identify project objectives, establish specifications, and a workplan to introduce technology solutions. NuProbe R&D scientists are experienced in understanding the challenges of integrating novel technologies into established workflows and work collaboratively to optimize the final product. Our bioinformatics experts can design solutions that can be applied to achieve desired user experience.


Our technologies provide best-in-class sensitivity for a wide range of genomic alterations and are compatible with a variety of sample types, including tissue and liquid biopsy.

Blocker Displacement

Rare allele enrichment technology by PCR that enables the selective amplification and detection of low-abundant sequence variants down to 0.01% variant allele frequency (VAF).

Quantitative Amplicon

NGS-based method that utilizes unique molecular identifiers (UMIs) and highly multiplexed partially nested PCR primer design to detect mutations and copy number variations with ultra-high sensitivity.

Working with NuProbe

Contact us to discuss how to develop a custom solution for your NGS or PCR assay needs.